| Literature DB >> 30343945 |
C Hamard1, X Mignard2, N Pecuchet3, N Mathiot4, H Blons3, P Laurent-Puig3, K Leroy5, A Lupo6, J Chapron4, F Giraud4, J Arrondeau7, F Goldwasser8, M Alifano9, D Damotte6, M Wislez10.
Abstract
Lung cancer is the leading cause of cancer deaths in France, with about 30,000 deaths per year. The overwhelming majority (90 %) are tobacco-related. The prognosis is dark but great therapeutic advances have been made with the development of targeted therapies first and then immunotherapy afterwards. These medications are conditioned to the expression of biomarkers that require specific tools in routine to measure them. We will detail in this chapter several techniques of anatomopathology, cytogenetics and molecular biology necessary for the detection of biomarkers in lung cancers, and their applications in thoracic oncology in 2018.Entities:
Keywords: Anatomopathologie; Anatomopathology; Biologie moléculaire; Biomarkers; Biomarqueurs; Cancer du poumon; Cytogenetics; Cytogénétique; Lung cancer; Molecular biology
Mesh：
Substances：
Year: 2018 PMID： 30343945 DOI： 10.1016/j.pneumo.2018.09.013
Source DB: PubMed Journal: Rev Pneumol Clin ISSN： 0761-8417